Abstract:1083 Introduction: High kidney uptake is a common feature of radiolabeled peptides, and this reduces detection sensitivity for lesions adjacent to kidneys and lowers maximum tolerated dose for radiotherapeutic application. The Met-Val-Lys (MVK) linker has been shown to reduce kidney uptake of 68Ga-labeled NOTA-conjugated peptides. The resulting lower kidney uptake was attributed to recognition and cleavage of the MVK sequence between MV by neprilysin (NEP), an endopeptidase found in abundance on the renal brush border lining. However, the use of NOTA chelator excludes application of such peptides for therapy using radioisotopes like 177Lu. For potential theranostic applications, DOTA is the preferred radiometal chelator. In this study, we evaluated if the MVK linker could be used to lower the kidney uptake of 68Ga-labeled DOTA-conjugated peptides as well. Methods: The DOTA conjugated linker (DOTA-AmBz-MVK(Ac)-OH; AmBz: 4-aminomethylbenzoyl), the expected cleaved metabolite DOTA-AmBz-Met-OH, and a PSMA-targeting ligand DOTA-AmBz-MVK(HTK01166)-OH were synthesized on solid-phase using standard Fmoc chemistry. All peptides were cleaved from resin with trifluoroacetic acid and purified by HPLC. Complexation with nonradioactive Ga and 68Ga was conducted in acetate (pH 4.5) and HEPES (pH 5.0) buffer, respectively. Renal proximal tubular brush-border membrane vesicles (BBMVs) were extracted from mouse kidneys. For NEP enzymatic recognition assay, Ga-68 labeled peptides were incubated with BBMVs (at 37 °C, 1 h) with/without the NEP inhibitor phosphoramidon (1 mg/well), and monitored by HPLC. In vivo stability was conducted in male NSG mice and the radiometabolites in blood (at 5 min post-injection, p.i.) and urine (15 min p.i.) were monitored by HPLC. PET/CT imaging and biodistribution studies were performed in mice bearing LnCap prostate cancer xenografts. Results: The DOTA-conjugated peptides and their Ga-complexes were successfully synthesized, and their identities were confirmed by MS analysis. Both in vitro and in vivo assays revealed complete cleavage (> 99%) of 68Ga-DOTA-AmBz-MVK(Ac)-OH with the expected 68Ga-DOTA-AmBz-Met-OH as the dominate radiometabolite (> 90%). The cleavage of 68Ga-DOTA-AmBz-MVK(Ac)-OH was inhibited (metabolite < 15%) in the presence of phosphoramidon in the in vitro enzyme assay. In vivo study showed that 68Ga-DOTA-AmBz-Met-OH was fast excreted from the body exclusively via the renal pathway with minimal kidney retention (<2.5 %ID/g). As for the PSMA-targeting ligand 68Ga-DOTA-AmBz-MVK(HTK01166)-OH, it was cleaved less effectively (79.6% intact) in the in vitro assay. The in vivo stability study also showed intact 68Ga-DOTA-AmBz-MVK(HTK01166)-OH (9%), the expected fragment 68Ga-DOTA-AmBz-Met-OH as a minor metabolite (35%) and an unidentified major radiometabolite (56%) in the blood. In the urine samples, only 68Ga-DOTA-AmBz-Met-OH (80%) and the intact tracer (20%) were detected. Imaging and biodistribution revealed lower tumor (3.98 %ID/g) and kidney (104 %ID/g) of 68Ga-DOTA-AmBz-MVK(HTK01166)-OH when compared to those of previously reported PSMA-targeting 68Ga-HTK01166 (14.1 and 147 %ID/g, respectively). Conclusions: We demonstrated that MVK can be inserted between DOTA and the targeting peptide sequences, and the resulting 68Ga-labeled peptides can be cleaved specifically between M-V by NEP. Due to very low kidney retention of the expected fragment, this strategy can be used to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides, and potentially their 177Lu-labeled analogs for radiotherapy. High renal uptake of 68Ga-DOTA-AmBz-MVK(HTK01166)-OH could be due to renal retention of the unknown metabolite. This underscores the importance of conducting a thorough structure-activity-relationship study when applying this strategy to reduce kidney uptake of radiopeptides.

Synthesis and Evaluation of Met-Val-Lys As a Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-conjugated Peptides

First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody

Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity Through Brush Border Membrane Enzyme-Mediated Degradation.

What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake

Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers.

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m

Preparation, In Vitro Affinity, and In Vivo Biodistribution of Receptor-Specific 68Ga-Labeled Peptides Targeting Vascular Endothelial Growth Factor Receptors

Imaging Bradykinin B1 Receptor with 68Ga-Labeled [Des-Arg10]kallidin Derivatives: Effect of the Linker on Biodistribution and Tumor Uptake.

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles

Optimizing the Design of Bradykinin B1 Receptor-Targeting Pet Tracers Via the Selection of Radiolabel Chelate

Improving Tumor Uptake and Pharmacokinetics of (64)Cu-Labeled Cyclic RGD Peptide Dimers with Gly(3) and PEG(4) Linkers.

Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles

Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression

Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting

Synthesis of Novel DOTA-/AAZTA-based Bifunctional Chelators: Solution Thermodynamics, Peptidomimetic Conjugation, and Radiopharmaceutical Evaluation

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Synthesis and Evaluation of a Novel Urea-Based 68Ga-Complex for Imaging PSMA Binding in Tumor.

Evaluation of A Cu-64-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for Pet of Tumors Expressing Alpha(V)Beta(3) Integrin

The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin

A Heterodimeric [Rgd-Glu-[(64)cu-no2a]-6-ahx-rm2] Αvβ3/grpr-Targeting Antagonist Radiotracer for PET Imaging of Prostate Tumors.